HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Aticaprant

a kappa opioid receptor antagonist; structure in first source

Also Known As:

3-fluoro4-(4-((2-(3,5-dimethylphenyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide; CERC-501; JNJ-67953964; LY2456302

Networked: 12 relevant articles (4 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Custodio-Patsey, Lilian: 2 articles (11/2021 - 01/2020)
2.	Smith, Bret N: 2 articles (11/2021 - 01/2020)
3.	Taylor, Bradley K: 2 articles (11/2021 - 01/2020)
4.	Butelman, Eduardo R: 2 articles (01/2018 - 01/2018)
5.	Fry, Rebecca S: 2 articles (01/2018 - 01/2018)
6.	Kimani, Rachel: 2 articles (01/2018 - 01/2018)
7.	Kreek, Mary Jeanne: 2 articles (01/2018 - 01/2018)
8.	Reed, Brian: 2 articles (01/2018 - 01/2018)
9.	Kreek, M J: 1 article (05/2022)
10.	Zhou, D C: 1 article (05/2022)

Related Diseases

1.	Hyperalgesia 01/01/2020 - "Sex studies revealed that LY2456302 (0.3 μg) reinstated hyperalgesia and pERK expression to a greater degree in female as compared to male mice. " 11/24/2021 - "LY2456302 reinstated hyperalgesia even when administered 13 months later, indicating that chronic postoperative pain vulnerability persists for over a year in a latent state of remission. " 01/01/2020 - "Both the prototypical KOR-selective inhibitors nor-BNI (0.1-10 μg) and the newer KOR inhibitor with more canonical pharmocodynamic effects, LY2456302 (0.1-10 μg), reinstated mechanical hyperalgesia. " 11/24/2021 - "To determine whether these pathways operate similarly between males and females or are under the inhibitory control of spinal κ opioid receptors (KOR), we allowed hyperalgesia to resolve after plantar incision and then blocked KOR with intrathecal administration of LY2456302, which reinstated hyperalgesia and facilitated touch-evoked immunoreactivity of phosphorylated extracellular signal-regulated kinase (pERK) in neurons (NeuN) but not astrocytes (GFAPs) nor microglia (Iba1). "
2.	Major Depressive Disorder (Major Depressive Disorders) 01/01/2020 - "We assessed, in a proof-of-concept pilot trial among patients with major depressive disorder with inadequate response to antidepressants, the efficacy of adjunctive CERC-501 (formerly LY2456302), a kappaselective opioid receptor antagonist. "
3.	Anhedonia 12/01/2020 - "They are also consistent with the clinical development of aticaprant as a therapeutic for stress-related disorders targeted at anhedonia, such as depression and post-traumatic stress disorder." 05/01/2022 - "Aticaprant, a selective and short-acting kappa-opioid receptor (KOR) antagonist, has recently been under development for new clinical implications (depression or anhedonia). "
4.	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 12/01/2020 - "They are also consistent with the clinical development of aticaprant as a therapeutic for stress-related disorders targeted at anhedonia, such as depression and post-traumatic stress disorder."
5.	Postoperative Pain 11/24/2021 - "LY2456302 reinstated hyperalgesia even when administered 13 months later, indicating that chronic postoperative pain vulnerability persists for over a year in a latent state of remission. "

Related Drugs and Biologics

1.	Aticaprant
2.	Antidepressive Agents (Antidepressants)
3.	Narcotic Antagonists (Opioid Antagonists)
4.	kappa Opioid Receptors (kappa Opioid Receptor)
5.	Ethanol (Ethyl Alcohol)
6.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
7.	mu Opioid Receptors (mu Opioid Receptor)
8.	Opioid Receptors (Opioid Receptor)
9.	Naltrexone (ReVia)
10.	Naloxone (Narcan)

Related Therapies and Procedures

1.	Therapeutics